Brokerages forecast that Corium International Inc (NASDAQ:CORI) will announce earnings per share of ($0.43) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Corium International’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.46). Corium International reported earnings per share of ($0.46) in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.5%. The company is expected to announce its next quarterly earnings results on Monday, February 12th.
On average, analysts expect that Corium International will report full year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.32). For the next fiscal year, analysts expect that the firm will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.69) to ($0.94). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Corium International.
CORI has been the topic of several research analyst reports. Needham & Company LLC raised their target price on shares of Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, November 20th. HC Wainwright set a $15.00 price objective on shares of Corium International and gave the company a “buy” rating in a report on Friday, November 17th. Zacks Investment Research downgraded shares of Corium International from a “buy” rating to a “sell” rating in a report on Tuesday, October 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a report on Friday, December 22nd. Finally, Jefferies Group set a $10.00 price objective on shares of Corium International and gave the company a “buy” rating in a report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $12.86.
In other news, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of Corium International stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $10.96, for a total value of $5,480,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 46.50% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. New York State Common Retirement Fund bought a new position in shares of Corium International in the second quarter valued at $158,000. California State Teachers Retirement System bought a new position in shares of Corium International in the second quarter valued at $263,000. Teachers Advisors LLC bought a new position in shares of Corium International in the second quarter valued at $272,000. TIAA CREF Investment Management LLC bought a new position in shares of Corium International in the second quarter valued at $411,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Corium International by 161.8% in the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 40,891 shares in the last quarter. Institutional investors own 89.35% of the company’s stock.
Shares of Corium International (NASDAQ CORI) traded up $0.16 during mid-day trading on Thursday, reaching $10.07. 102,081 shares of the company’s stock traded hands, compared to its average volume of 209,746. The company has a quick ratio of 6.80, a current ratio of 7.04 and a debt-to-equity ratio of 1.89. The firm has a market cap of $359.93, a P/E ratio of -6.03 and a beta of 1.26. Corium International has a 52-week low of $2.67 and a 52-week high of $12.32.
ILLEGAL ACTIVITY WARNING: “Corium International Inc (CORI) Expected to Announce Earnings of -$0.43 Per Share” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/corium-international-inc-cori-expected-to-announce-earnings-of-0-43-per-share.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Get a free copy of the Zacks research report on Corium International (CORI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.